News

IPI || Why the right approach to data management will enable the potential of small-molecule RNA sodifiers as drug targets to be fulfilled

Over the past 5 decades or so, the growing understanding that RNA can influence protein function through routes other than direct translation has opened the prospect of discovering small molecules for tackling diseases in novel ways.

whitepages icon x

Pharma’s Almanac | What do you think most differentiates the U.S. pharma/biopharma industry or the market?

Paradigm4’s Marilyn Matz reflects on the understanding complex biological phenomena has required concurrent advances in experimental methods and computing power.

whitepages icon x

Manufacturing Chemist | Multidimensional data analysis platforms: meeting new FDA calls for consistent evidence from CGT developers

Recent news that the US Food and Drug Administration (FDA) will ask cell and gene therapy (CGT) developers to provide more consistent evidence with their submissions has resulted in drug makers delaying development plans — and working on new ways to address the agency’s concerns

whitepages icon x

WALTHAM, Mass. || Paradigm4, Inc. announces the general availability of flexFS

Paradigm4 announces the general availability of flexFS, a hyperscale file system designed for AI/ML and large file data workloads, providing unparalleled throughput at 50% lower cost